Cited by 285Cancer Immunotherapy and Biomarkersinterferon and immune responsesImmunotherapy and Immune Responses

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Open access

Lu, Changzheng, Guan, Junhong, Lu, Steve, Jin, Qihuang, Rousseau, Benoit, Lu, Tianshi, Stephens, Dennis, Zhang, Hongyi, Zhu, Jiankun, Yang, Mingming, Ren, Zhenhua, Liang, Yong, Liu, Zhida, Han, Chuanhui, Liu, Longchao, Cao, Xuezhi, Zhang, Anli, Qiao, Jian, Batten, Kimberly, Chen, Mingyi, Castrillon, Diego H., Wang, Tao, Li, Bo, Diaz, Luis A., Li, Guo-Min, Fu, Yang-Xin·2021·Cancer Cell

DOI 10.1016/j.ccell.2020.11.006PMC PMC9477183

Open this paper in CoChat — free account Open PDF

Abstract

Increased neoantigens in hypermutated cancers with DNA mismatch repair deficiency (dMMR) are proposed as the major contributor to the high objective response rate in anti-PD-1 therapy. However, the mechanism of drug resistance is not fully understood. Using tumor models defective in the MMR gene Mlh1 (dMLH1), we show that dMLH1 tumor cells accumulate cytosolic DNA and produce IFN-β in a cGAS-STING-dependent manner, which renders dMLH1 tumors slowly progressive and highly sensitive to checkpoint blockade. In neoantigen-fixed models, dMLH1 tumors potently induce T cell priming and lose resistance to checkpoint therapy independent of tumor mutational burden. Accordingly, loss of STING or cGAS in tumor cells decreases tumor infiltration of T cells and endows resistance to checkpoint blockade. Clinically, downregulation of cGAS/STING in human dMMR cancers correlates with poor prognosis. We conclude that DNA sensing within tumor cells is essential for dMMR-triggered anti-tumor immunity. This study provides new mechanisms and biomarkers for anti-dMMR-cancer immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.11.006

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citation
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citation
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Marabelle, A., Le, D. T., Ascierto, P. A., Giacomo, A. M. D., Jesus‐Acosta, A. D., Delord, J., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,122
Self-citation
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836

Flagged first, then by citations

Show all 60 references

1 of the 60 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 285

The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges
Zhou, Z., Huang, S., Fan, F., Xu, Y., Moore, C., Li, S., & Han, C. (2024) · Medical Review · doi:10.1515/mr-2023-0061 · Cited by 25
Self-citation
Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma
Liu, J., Li, X., Chen, J., Guo, J., Guo, H., Zhang, X., Fan, J., Zhang, K., Mao, J., & Zhou, B. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02579-1 · Cited by 24
Unveiling the crossroads of STING signaling pathway and metabolic reprogramming: the multifaceted role of the STING in the TME and new prospects in cancer therapies
Wang, S., Qin, L., Liu, F., & Zhang, Z. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02169-0 · Cited by 24
KIF2C is a Biomarker Correlated With Prognosis and Immunosuppressive Microenvironment in Human Tumors
Zhang, X., Li, Y., Hu, P., Xu, L., & Qiu, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.891408 · Cited by 25
Regulation of STING activation by phosphoinositide and cholesterol
Li, J., Tan, J. X., Chen, Z. J., Zhang, X., & Bai, X.-C. (2026) · Nature · doi:10.1038/s41586-025-10076-0 · Cited by 28
Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth
Ding, C., Du, M., Xiong, Z., Wang, X., Li, H., He, E., Han, L., Dang, Y., Lü, Q., Li, S., et al. (2023) · Chemical Science · doi:10.1039/d3sc01896b · Cited by 23
Self-citation
SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer
Su, Z., He, Y., You, L., Chen, J., Zhang, G., & Liu, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-76298-w · Cited by 29
Self-citation
Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy
Czajkowski, D., Szmyd, R., & Gee, H. E. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13413 · Cited by 24
Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity
Liu, Y., Yang, F., Wang, X., Yang, B., Li, M., & Luo, Z. Y. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.026 · Cited by 24
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies
Anderson, K. G., Braun, D. A., Buqué, A., Gitto, S. B., Guerriero, J. L., Horton, B. L., Keenan, B. P., Kim, T. S., Overacre-Delgoffe, A. E., Ruella, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006533 · Cited by 22
Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers
Romero, J. M., Titmuss, E., Wang, Y., Vafiadis, J., Pacis, A., Jang, G. H., Zhang, A. X. W., Golesworthy, B., Lenko, T., Williamson, L., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00428-2 · Cited by 21
Self-citation
N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma
Miranda, A., Pattnaik, S., Hamilton, P. T., Fuss, M. A., Kalaria, S., Laumont, C. M., Smazynski, J., Mesa, M., Banville, A. C., Jiang, X., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj5428 · Cited by 21
Activation of cGAS-STING Pathway Is Associated with MSI-H Stage IV Colorectal Cancer
Kunac, N., Degoricija, M., Viculin, J., Omerović, J., Terzić, J., Vilović, K., & Korać-Prlić, J. (2022) · Cancers · doi:10.3390/cancers15010221 · Cited by 21
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity
Liu, H., Su, H., Wang, F., Dang, Y., Ren, Y., Yin, S., Lu, H., Zhang, H., Wu, J., Xu, Z., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112275 · Cited by 21
Self-citation
TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity
Niu, Y., Ding, C., Wang, Q., Yin, J., Li, L., Liu, W., Wang, X., & Huang, L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03513-5 · Cited by 23
Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?
Lazo, P. A. (2022) · Cancers · doi:10.3390/cancers14164050 · Cited by 20
GAS-STING: a classical DNA recognition pathways to tumor therapy
Wang, X., Lin, M., Zhu, L., & Ye, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200245 · Cited by 22
MicroRNAs and the DNA damage response: How is cell fate determined?
Visser, H., & Thomas, A. D. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103245 · Cited by 20
Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma
Xue, Y., Wang, Y., Ren, Z., & Yu, K. (2024) · Oncogene · doi:10.1038/s41388-024-03248-1 · Cited by 20
Self-citation
The role of type I interferon signaling in myeloid anti-tumor immunity
Meyer, S. P., Bauer, R., Brüne, B., & Schmid, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1547466 · Cited by 22
Recent advances in lanthanide-doped up-conversion probes for theranostics
Xu, D., Li, C., Li, W., Lin, B., & Lv, R. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1036715 · Cited by 18
Immunogenic chemotherapy: great potential for improving response rates
Huang, X., Ren, Q., Yang, L., Cui, D., Ma, C., Zheng, Y., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1308681 · Cited by 21
Clinical Significance of Disulfidptosis-related Genes and Functional Analysis in Gastric Cancer
Yan, J., Fang, Z., Shi, M., Tu, C., Zhang, S., Jiang, C., Li, Q., & Shao, Y. (2024) · Journal of Cancer · doi:10.7150/jca.91796 · Cited by 20
Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cancer
Oyama, K., Nakata, K., Tsutsumi, C., Hayashi, M., Zhang, B., Mochida, Y., Shinkawa, T., Hirotaka, K., Zhong, P., Date, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0830 · Cited by 18
NLRP3 activation promotes cGAS/STING signaling and antitumor immunity by colorectal cancer cells
Mowat, C., Schiller, D., & Baker, K. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04088-y · Cited by 18
Combretastatin A4-Based Albumin Nanoparticles Remodeling the Tumor Immune Microenvironment to Enhance T Cell Immunotherapy in Colon Cancer
Wang, Y., Liu, Y., Wang, L., Chen, Z., Ye, Q., Chen, K., Zhao, C., Yang, M., Xia, W., Zhang, M., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c03638 · Cited by 17
Self-citation
Potential biomarkers for immunotherapy in non-small-cell lung cancer
Wang, X., Qiao, Z.-Y., Aramini, B., Lin, D. X., Li, X., & Fan, J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10074-y · Cited by 18
High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer
Guo, J., Tang, B., Fu, J., Zhu, X., Xie, W.-L., Wang, N., Ding, Z., Song, Z., Yang, Y., Xu, G., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00885-8 · Cited by 17
Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges
Qiu, B., Kline, C., & Mueller, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.674596 · Cited by 17
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
Roudko, V., Valle, D. M. D., Radkevich, E., Kelly, G., Hui, X., Patel, M., Gonzalez‐Kozlova, E., Tuballes, K., STREICHER, H. Z., Atale, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010541 · Cited by 16
Inter-Tissue Communication Mechanisms via Exosomes and Their Implications in Metabolic Diseases: Opportunities for Pharmacological Regulation
Chimal‐Vega, B., Maldonado-Arvizu, J. E., Hernández-Avalos, A. D., Díaz‐Villanueva, J. F., Ávila‐Barrientos, L. P., & García‐González, V. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5010011 · Cited by 20
Network Pharmacology Research and Dual-omic Analyses Reveal the Molecular Mechanism of Natural Product Nodosin Inhibiting Muscle-Invasive Bladder Cancer in Vitro and in Vivo
Hao, X., Fan, H., Yang, J., Tang, J., Zhou, J., Zhao, Y., Huang, L., & Xia, Y. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00400 · Cited by 16
Genetic and immune landscape evolution in MMR‐ deficient colorectal cancer
Challoner, B. R., Woolston, A., Lau, D. K., Buzzetti, M., Fong, C., Barber, L. J., Anandappa, G., Crux, R., Assiotis, I., Fenwick, K., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6228 · Cited by 19
Intratumoral and peritumoral CT-based radiomics for predicting the microsatellite instability in gastric cancer
Chen, X., Zhuang, Z., Pen, L., Xue, J., Zhu, H., Zhang, L., & Wang, D. (2024) · Abdominal Radiology · doi:10.1007/s00261-023-04165-9 · Cited by 16
T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Cho, N. W., Guldberg, S. M., Nabet, B. Y., Zeng, J., Kim, E. J., Hiam-Galvez, K. J., Yee, J. L., DeBarge, R., Tenvooren, I., Ashitey, N. A., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0416 · Cited by 16
EXOTLR1/2-STING: A Dual-Mechanism Stimulator of Interferon Genes Activator for Cancer Immunotherapy
Wang, T., Hu, H., Zhao, L., Zhuo, S., Su, J., Feng, G.-H., & Li, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c18056 · Cited by 15
Self-citation
Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation
Alshebremi, M., Tomchuck, S. L., Myers, J. T., Kingsley, D. T., Eid, S., Abiff, M., Bonner, M., Saab, S. T., Choi, S. H., & Huang, A. Y.-C. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006608 · Cited by 14
“Detection of cytosolic dsDNA in the context of viral and bacterial infections, 26–29 aging and damaged cells, 30 or cancer, 31–33 is performed by the cytoplasmic DNA sensor, cGAS. cGAS catalyzes the formation of the second messenger cyclic dinucleotide (CDN), 2 ′ 3 ′ -cyclic- GMP-AMP (cGAMP).”
ACSL4 knockdown inhibits colorectal cancer progression through stimulating anti-tumor immunity
Liu, Y., Jiang, X., Jing, D., Lin, Y., Gao, R., Zhao, Q., Da, H., Ren, Y., Cao, Q., Liu, N., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101194 · Cited by 14
DNA damage repair and cancer immunotherapy
Xiang, Z., Liu, H., & Hu, Y. (2023) · Genome Instability & Disease · doi:10.1007/s42764-023-00098-1 · Cited by 13
HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation
Zhang, W., Yang, J.-G., Wang, B.-K., Lu, Y.-T., Yang, J.-B., Zhong, W.-Q., Yu, Z.-Y., Qin, Z., Xiao, B., Wang, K.-M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113352 · Cited by 15
DNA repair deficiency and the immune microenvironment: A pathways perspective
Zhou, Y., & Mouw, K. W. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103594 · Cited by 16
Stimulator of Interferon Genes Protein (STING) Expression in Cancer Cells: A Tissue Microarray Study Evaluating More than 18,000 Tumors from 139 Different Tumor Entities
Menz, A., Zerneke, J., Viehweger, F., Büyücek, Ş., Dum, D., Schlichter, R., Hinsch, A., Bawahab, A. A., Fraune, C., Bernreuther, C., et al. (2024) · Cancers · doi:10.3390/cancers16132425 · Cited by 14
Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors
Wang, S., Zheng, Q.-Y., Hong, W.-F., Tang, B., Hsu, S.-J., Zhang, Y., Zheng, X., Zeng, Z.-C., Gao, C., Ke, A., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110424 · Cited by 17
The role of cGAS-STING signaling pathway in colorectal cancer immunotherapy: Mechanism and progress
Luo, Y. Q., Liang, G., Zhang, Q., & Luo, B. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113447 · Cited by 17
Combined treatment of small cell lung cancer using radiotherapy and immunotherapy: Challenges and updates
Cao, Z., Deng, K., Jiang, J., Tian, K., & Wang, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117727 · Cited by 16
T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers
Tang, S., Che, X., Wang, J., Li, C., He, X., Hou, K., Zhang, X., Guo, J., Yang, B., Li, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58958-1 · Cited by 13
Evaluation of immunotherapy efficacy in gynecologic cancer
Jiang, G., Wu, Q., & Li, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1061761 · Cited by 16
Self-citation
Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough
Gerlinger, M. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.016 · Cited by 14
CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models
Bao, Y., Chang, Y., Tien, J. C.-Y., Cruz, G., Yang, F., Mannan, R., Mahapatra, S., Paturu, R., Cao, X., Su, F., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci193745 · Cited by 13
Self-citation
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
Choo, J. R.-E., Sargsyan, A., Khachatryan, V., Lonardi, S., Pietrantonio, F., Sundar, R., Klempner, S. J., & Janjigian, Y. Y. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01134-1 · Cited by 17
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Marine, J., Bartok, O., Sagie, S., Vitiello, P. P., Bardelli, A., Weller, C., Chang, T., Tonelli, C., Spranger, S., Ruppin, E., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.025 · Cited by 16
Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory
El‐Hajjar, M., Gerhardt, L., Hong, M. M. Y., Krishnamoorthy, M., Figueredo, R., Zheng, X., Koropatnick, J. D., & Vareki, S. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.025 · Cited by 13
Cytoplasmic DNAs: Sources, sensing, and roles in the development of lung inflammatory diseases and cancer
He, X., Sun, Y., Lu, J., Naz, F., Ma, S., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117760 · Cited by 14
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
Hodgins, J. J., Abou‐Hamad, J., O’Dwyer, C., Hagerman, A., Yakubovich, E., de Souza, C. T., Marotel, M., Buchler, A., Fadel, S., Park, M. M., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20221721 · Cited by 19
Modulation of immune responses by DNA damage signaling
Uchihara, Y., Permata, T. B. M., Sato, H., & Shibata, A. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103135 · Cited by 16
Protein arginine methyltransferase 6 enhances immune checkpoint blockade efficacy via the STING pathway in MMR-proficient colorectal cancer
Duan, J., Chen, T., Li, Q., Zhang, Y., Lu, T., Xue, J., Sun, Y., Gao, L., & Zhang, Y. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010639 · Cited by 14
Self-citation
Genome instability and crosstalk with the immune response
Chabanon, R. M., Danlos, F. X., Ouali, K., & Postel-Vinay, S. C. (2025) · Genome Medicine · doi:10.1186/s13073-025-01509-6 · Cited by 16
Tumors cells with mismatch repair deficiency induce hyperactivation of pyroptosis resistant to cell membrane damage but are more sensitive to co-treatment of IFN-γ and TNF-α to PANoptosis
Li, H., Ni, H., Li, Y., Zhou, A., Qin, X., Li, Y., Che, L., Mo, H., Qin, C., & Li, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01984-7 · Cited by 12
Inhibition of O-GlcNAc transferase activates type I interferon-dependent antitumor immunity by bridging cGAS-STING pathway
Chen, J., Zhao, B. L., Dong, H., Li, T., Cheng, X., Gong, W., Wang, J., Zhang, J., Xin, G., Yu, Y., et al. (2024) · eLife · doi:10.7554/elife.94849.3 · Cited by 19
Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response
Barcellos‐Hoff, M. H., & Yom, S. S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00819-6 · Cited by 13
Chromatin-remodeling factor BAZ1A/ACF1 targets UV damage sites in an MLL1-dependent manner to facilitate nucleotide excision repair
Koyauchi, T., Niida, H., Motegi, A., Sakai, S., Uchida, C., Ohhata, T., Iijima, K., Yokoyama, A., Suda, T., & Kitagawa, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119332 · Cited by 11
Eliminating xenobiotics organic compounds from greywater through green synthetic nanoparticles
Heshammuddin, N. A., Al-Gheethi, A. A. S., Mohamed, R. M. S. R., & Khamidun, M. H. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115316 · Cited by 12
Higher Levels of Tumour-Infiltrating Lymphocytes (TILs) are Associated with a Better Prognosis, While CDK5 Plays a Different Role Between Nonmetastatic and Metastatic Colonic Carcinoma
Wang, Q., Yin, R., Chen, X., Hu, B., Jiang, B., Tang, W., Zhang, X., Jin, X., Ying, M., & Fu, J. (2023) · Cancer Control · doi:10.1177/10732748231169396 · Cited by 11
KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer
Zheng, J., Feng, H., Lin, J., Zhou, J., Xi, Z., Zhang, Y., Ling, F., Liu, Y., Wang, J., Hou, T., et al. (2024) · Advanced Science · doi:10.1002/advs.202309983 · Cited by 10
Advances in cancer biomarkers: current detection strategies and challenges
Liu, Z., Huang, Z., Chen, X., Zhang, L., Wu, Q. D., Li, L., Yu, C., & Wei, J. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217242 · Cited by 10
Self-citation
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology
DeWitt, J. T., Raghunathan, M., & Haricharan, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.10.001 · Cited by 10
Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade
Moore, J., Gkantalis, J., Guix, I., Chou, W. S., Yuen, K. C. Y., Lazar, A., Spitzer, M. H., Combes, A. J., & Barcellos‐Hoff, M. H. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010528 · Cited by 10
Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma
Lu, X., Green, B. L., Xie, C., Liu, C., & Chen, X. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100723 · Cited by 10
Long-Read Nanopore Sequencing Identifies Mismatch Repair-Deficient Related Genes with Alternative Splicing in Colorectal Cancer
Qu, H., Wang, Z. J., Zhang, Y., Zhao, B., Jing, S., Zhang, J., Ye, C., Xue, Y., & Yang, L. (2022) · Disease Markers · doi:10.1155/2022/4433270 · Cited by 10
NLRC5 potentiates anti-tumor CD8+ T cells responses by activating interferon-β in endometrial cancer
Zhang, J., Guo, B., Chen, J.-H., Liu, X.-J., Zhang, J., Zhu, H., Wang, W., Tang, Z., Wei, B., Cao, Y., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101742 · Cited by 10
DNA-PK–Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance
Wang, H., Zhang, Y., Tian, Y., Yang, W., Wang, Y., Hou, H., Pan, H., Pei, S., Zhu, H., Gu, Z., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-0744 · Cited by 9
Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies
Hung, J., Teng, C.-F., Hung, H.-C., Chen, Y., Chen, P.-J., Ho, C., Chuang, C.-H., & Huang, W. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101546 · Cited by 10
DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition
Brooksbank, K., & Martin, S. A. (2023) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2023.106477 · Cited by 10
Dietary γ-mangostin triggers immunogenic cell death and activates cGAS signaling in acute myeloid leukemia
Long, Z., Wang, J., Qiu, S., Zhang, Y., Wu, S., Lei, X., Huang, Z., Chen, J., Yang, Y., Zhang, X., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106973 · Cited by 9
Inhibition of Aurora Kinase Induces Endogenous Retroelements to Induce a Type I/III IFN Response via RIG-I
Choy, L., Norris, S., Wu, X., Kolumam, G. A., Firestone, A. J., Settleman, J. E., & Stokoe, D. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0432 · Cited by 12
Mismatch repair gene MSH6 correlates with the prognosis, immune status and immune checkpoint inhibitors response of endometrial cancer
Zhou, L., Xiao, H., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1302797 · Cited by 11
Biological and clinical implications of a model of surveillance immunity
Willmann, K. L., & Moita, L. F. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191645 · Cited by 7
Mismatch Repair as a Dynamic and Clinically Actionable Vulnerability in Cancer
Piumatti, E., Vitiello, P. P., Amodio, V., Bardelli, A., & Germano, G. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2255 · Cited by 12
Striking the right balance with type I interferon signalling in cancer
Chadwick, T. B., So, J., Hertzog, P. J., Haynes, N. M., & Parker, B. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00915-1 · Cited by 14
STING promotes invasion and migration of uveal melanoma through p38‑MAPK signaling
Zhou, X., Meng, F., Xu, B., Ma, R., Cheng, Y., Wu, J., & Qian, J. (2023) · Oncology Reports · doi:10.3892/or.2023.8682 · Cited by 8
Systematic analysis of the prognostic value and immunological function of LTBR in human cancer
Wu, Y., Zhao, S., Guo, W., Liu, Y., Requena, M., Alarcón, R., & Wei, R. (2024) · Aging · doi:10.18632/aging.205356 · Cited by 8
Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression
Peng, K., Liu, Y., Liu, S., Wang, Z., Zhang, H., He, W., Jin, Y., Wang, L., Xia, X., & Xia, L. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00916-y · Cited by 8
Self-citation
The HLA-I landscape confers prognosis and antitumor immunity in breast cancer
Ding, X.-H., Xiao, Y., Chen, F., Liu, C., Fu, T., Shao, Z., & Jiang, Y. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae151 · Cited by 9
Systemic inflammation in response to radiation drives the genesis of an immunosuppressed tumor microenvironment
Ma, L., Mao, J., & Barcellos‐Hoff, M. H. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101164 · Cited by 9
Radiation-induced non-targeted effect of immunity provoked by mitochondrial DNA damage triggered cGAS/ AIM2 pathways
Zhang, W., Chen, S., Guan, H., & Zhou, P. (2022) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2022.05.002 · Cited by 10
Pathways to hypermutation in high-grade gliomas: Mechanisms, syndromes, and opportunities for immunotherapy
Haynes, T., Gilbert, M. R., Breen, K., & Yang, C. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae105 · Cited by 7
Dual-mode immunotherapy: ultrasound responsive zinc-based nano-contract agents synergistically activate the GAS-STING pathway for enhanced tumor sono-metalloimmunotherapy
Zeng, X., Wang, X., Zhao, Y., Guo, L., Sun, X., Shang, M., Huang, S., Liu, R. R., Zhang, J., Xiao, S., et al. (2025) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2025.107494 · Cited by 7
Chemotherapy-induced CA-repeat DNA fragments in breast cancer trigger antitumor immune responses
Zhang, X., Huang, P., Chen, H., Yang, C., Yang, X., Liu, Y., Wu, B., Zeng, W., Saw, P. E., Ye, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02289-2 · Cited by 7
Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer
Ding, Y., Zheng, Y., Ding, B., Feng, S., Zhang, Y., & Shen, Y. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01207-5 · Cited by 7
Mutational Signatures in Colorectal Cancer: Translational Insights, Clinical Applications, and Limitations
Crisafulli, G. (2024) · Cancers · doi:10.3390/cancers16172956 · Cited by 10
Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity
Wang, C., Chang, Y., Sie, Z., Ho, A., Chang, J., Peng, C., & Cheng, C. (2021) · Cells · doi:10.3390/cells10102515 · Cited by 7
The effect of Chaihu-shugan-san on cytotoxicity induction and PDGF gene expression in cervical cancer cell line HeLa in the presence of paclitaxel +cisplatin
Xue, J., Zhu, L., Yanan, J., & Yanliang, G. (2021) · Cellular and Molecular Biology · doi:10.14715/cmb/2021.67.3.21 · Cited by 7
Tumors with microsatellite instability upregulate TREX1 to escape antitumor immunity
Xu, Y., Zhou, Z., Chen, W.-Z., Du, F., Huang, S., Qi, J., Zeng, Y., Su, H., Wang, J., Xiao, C., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250265 · Cited by 6
Self-citation
Tumor immunology and immunotherapy for endometrial cancer
Murakami, K., Takamura, S., Kakimi, K., & Matsumura, N. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2463091 · Cited by 11
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
Gueble, S. E., Vasquez, J. C., & Bindra, R. S. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01024-5 · Cited by 6
Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients
Zhang, D., Wang, Y., Zhao, F., & Yang, Q. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106866 · Cited by 5
The entanglement of DNA damage and pattern recognition receptor signaling
Ha, C. T., Tageldein, M. M., & Harding, S. M. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103595 · Cited by 6
Prognostic and predictive factors in advanced upper gastrointestinal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis of the current evidence
Wang, P., Chen, P., Yang, W., Yang, W., Liu, W., Yue, S., & Luo, Q. (2024) · BMC Cancer · doi:10.1186/s12885-024-12998-w · Cited by 5
Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers
Huang, H., Chen, Z., Mao, X., Jiang, J., Xi, Y., Wan, Y., Wang, L., Chen, X., & Hu, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012121 · Cited by 5
Targeting DNA-PK
Novotný, J. P., Mariño‐Enríquez, A., & Fletcher, J. A. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_16 · Cited by 5

Authors: Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., Ren, Z., Liang, Y., Liu, Z., Han, C., Liu, L., Cao, X., Zhang, A., Qiao, J., Batten, K., Chen, M., Castrillon, D. H., Wang, T., Li, B., Diaz, L. A., Li, G.-M., & Fu, Y.-X.
Affiliations: The University of Texas Southwestern Medical Center (US)
Howard Hughes Medical Institute (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Li, Guo-Min
Fu, Yang-Xin
ORCID: Lu, Changzheng
Guan, Junhong
Lu, Steve
Jin, Qihuang
Lu, Tianshi
Zhang, Hongyi
Zhu, Jiankun
Yang, Mingming
Ren, Zhenhua
Liang, Yong
Liu, Zhida
Han, Chuanhui
Liu, Longchao
Cao, Xuezhi
Zhang, Anli
Qiao, Jian
Chen, Mingyi
Wang, Tao
Li, Bo
Diaz, Luis A.
Li, Guo-Min
Fu, Yang-Xin
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2021-01
Volume: 39
Issue: 1
Pages: 96-108.e6
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2020.11.006
PMC: PMC9477183
OpenAlex: W3112754342
Cited by: 285
References: 60
Citations by year: 2026: 36 · 2025: 51 · 2024: 53 · 2023: 66 · 2022: 46 · 2021: 32
FWCI: 13.09
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Entertainment Industry Foundation
Amaldi Research Center
Astellas Pharma US
Johns Hopkins University
Merck
University of Texas Southwestern Medical Center (RP180725)
Novartis
Bayer Fund
Cancer Prevention and Research Institute of Texas (RR150072, RR160101)
Jounce Therapeutics
Gilead Sciences
Servier
American Association for Cancer Research
National Institutes of Health (1R01CA245318-01A1, 5P30CA142543)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: mismatch repair deficiency, MLH1, cytosolic DNA sensing, cGAS-STING pathway, interferon-beta, neoantigens, anti-PD-1 therapy, immune checkpoint blockade, tumor immunogenicity, T cell priming, tumor mutational burden, drug resistance, prognostic factors, cancer immunotherapy
MeSH terms: MutL Protein Homolog 1, Immune Checkpoint Inhibitors, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Animals, Female, Humans, Membrane Proteins, Neoplasm Transplantation, Neoplasms, Nucleotidyltransferases, Prognosis, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Interferon-beta, Cell Line, Tumor, Mice, DNA Mismatch Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks